Phase 3 Study of S6G5T-3 (Twyneo) in Acne Vulgaris

Phase 3, randomised, double-blind trial in acne vulgaris comparing S6G5T-3 (Twyneo) with Vehicle (2 arms). Primary endpoints: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline at 12 weeks, Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12 and 1 more. Started Dec 2018; status: completed.